Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fexofenadine is a second-generation antihistamine used to relieve symptoms of seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives), such as runny nose; sneezing; red or itchy eyes; itching of the nose or throat; and skin rash. It works by selectively blocking peripheral histamine H1 receptors in the body—preventing histamine from binding and triggering allergy symptoms. Unlike first-generation antihistamines that cross the blood-brain barrier and cause sedation or drowsiness by acting on central nervous system H1 receptors, fexofenadine is less likely to cause drowsiness due to its selectivity for peripheral receptors. The drug was FDA approved in 1996[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fexofenadine.